Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) Equity Ratio (2024 - 2025)

Prelude Therapeutics' Equity Ratio history spans 2 years, with the latest figure at 0.49 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 35.15% year-over-year to 0.49; the TTM value through Dec 2025 reached 0.49, down 35.15%, while the annual FY2025 figure was 0.49, 35.15% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.49 at Prelude Therapeutics, down from 0.62 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.85 in Q1 2024 and bottomed at 0.49 in Q4 2025.